7-Hydroxystaurosporine
- Generic Name
- 7-Hydroxystaurosporine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H26N4O4
- CAS Number
- 112953-11-4
- Unique Ingredient Identifier
- 7BU5H4V94A
- Associated Conditions
- -
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Phase 1
Completed
- Conditions
- LeukemiaLymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Registration Number
- NCT00045513
- Locations
- ๐จ๐ฆ
Princess Margaret Hospital at University Health Network, Toronto, Ontario, Canada
๐จ๐ฆMcMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
๐จ๐ฆLondon Health Sciences Centre, London, Ontario, Canada
UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00042861
- Locations
- ๐บ๐ธ
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
Phase 1
Completed
- Conditions
- LymphomaLeukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019838
- Locations
- ๐บ๐ธ
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
๐บ๐ธNCI - Center for Cancer Research, Bethesda, Maryland, United States
A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Phase 1
Completed
- Conditions
- Breast CancerProstatic NeoplasmLymphomaNeoplasm
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00001444
- Locations
- ๐บ๐ธ
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath